Pharmacologic circumvention of multidrug resistance

Cytotechnology

Volumn 12, Issue 1-3, 1993, Pages 171-212

  Ford, James M ^a   Hait, William N ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

cancer chemotherapy; chemosensitizer; modulation; multidrug resistance

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALMODULIN; CARRIER PROTEIN; DRUG DERIVATIVE; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; MEMBRANE PROTEIN; STEROID; VINBLASTINE; VINDOLINE;

ANIMAL; CELL CULTURE; CELL LINE; DRUG EFFECT; DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMAL; ANTIBIOTICS; ANTINEOPLASTIC AGENTS; CALCIUM CHANNEL BLOCKERS; CALMODULIN; CARRIER PROTEINS; CELL LINE; DRUG RESISTANCE; HUMAN; IMMUNOSUPPRESSIVE AGENTS; MEMBRANE GLYCOPROTEINS; P-GLYCOPROTEIN; STEROIDS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 0027714411     PISSN: 09209069     EISSN: 15730778     Source Type: Journal    
DOI: 10.1007/BF00744664     Document Type: Article

References (319)

1. Structure-activity relationships of phenothiazines and related drugs for inhibition of protein kinase C
2. Effects of phorbol 12-myristate 13-acetate on drug accumulation and P-glycoprotein phosphorylation in sensitive and multidrug resistant MCF-7 cells
3. Antibody-mediated specific binding and cytotoxicity of liposome-entrapped doxorubicin to lung cancer cells in vitro
4. Studies of high-dose megestrol acetate: potential applications in cachexia
5. Most drugs that reverse multidrug resistance inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analog
6. Synthetic isoprenoid photoaffinity labeling of P-glycoprotein specific to multidrug-resistant cells
7. Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis
8. The role of protein kinase C and the phosphatidylinositol cycle in multidrug resistance in human ovarian cancer cells
9. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity
10. Role of protein kinase C in phosphorylation of vinculin in Adriamycin-resistant HL-60 leukemia cells
11. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus
12. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype
13. Potentiation of some anticancer agents by dipyridamole against drug-sensitive and drug-resistant cancer cell lines
14. Isolation and characterization of PKC-L, a new member of the protein kinase C-related gene family specifically expressed in lung, skin, and heart
15. Monitoring the chemosensitizing effects of toremifene with flow cytometry in estrogen receptor negative multidrug resistant human breast cancer cells
16. Modulation of P-glycoprotein phosphorylation and drug transport by sodium butyrate
17. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells
18. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR)
19. Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine
20. Phase I study of vinblastine and verapamil given by concurrent iv infusion
21. Criteria for analyzing interactions between biologically active agents
22. Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype
23. Multidrug resistant human neurobastoma cells are more differentiated than controls and retinoic acid further induces lineage-specific differentiation
24. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic and cytogenetic studies
25. Two distinct signal transduction pathways in T lymphocytes are inhibited by alternative complexes formed between an immunophilin and either FK506 or rapamycin
26. Selective regulation of expression of protein kinase C isoenzymes in multidrug-resistant MCF-7 cells: functional significance of enhanced expression of PKC α
27. Selective antimitochondrial agents inhibit calmodulin
28. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative
29. Modulation of drug cytotoxicity in wild-type and multidrug-resistant tumor cells by stereoisomeric series of C-20′-vinblastine congeners that lack antimicrotubule activity
30. Characterization of the azidopine and vinblastine binding site of P-glycoprotein
31. Two different regions of phosphoglycoprotein are photoaffinity-labeled by azidopine
32. Phase I trial of dipyridamole with 5-fluorouracil and folinic acid
33. 8-Cl-cAMP, a site-selective cAMP analog as a novel agent that inhibits the promoter activity of multidrug-resistance gene
34. Coinduction of MDR-1 multidrug resistance and cytochrome P-450 genes in rat liver by xenobiotics
35. Preparation and utility of a radioiodinated analogue of daunomycin in the study of multidrug resistance
36. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis
37. Acute intoxication with verapamil
38. Action of calcium antagonists on multidrug resistant cells
39. Modulation of drug permeability in Chinese hamster ovary cells — possible role for phosphorylation of surface glycoproteins
40. Mechanisms regulating cell resistance to Adriamycin — evidence that drug accumulation in resistant cells is modulated by phosphorylation of a plasma membrane glycoprotein
41. Evidence that Adriamycin resistance in Chinese hamster lung cells is regulated by phosphorylation of a plasma membrane glycoprotein
42. Potentiation of bleomycin lethality by anticalmodulin drugs: a role for calmodulin in DNA repair
43. Enhancement of anthracycline growth inhibition in parent and multidrug-resistant Chinese hamster ovary cells by cyclosporin A and its analogues
44. Correlation of protein kinase C translocation, P-glycoprotein phosphorylation and reduced drug accumulation in multidrug resistant human KB cells
45. Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells
46. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma
47. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood
48. Enhancement of adriamycin cytotoxicity in a multidrug resistant Chinese hamster ovary (CHO) subline, CHO-Adr, by toremifene and its modulation by alpha 1 acid glycoprotein
49. Reversal of acquired resistance to adrimycin in CHO cells by tamoxifen and 4-hydroxy tamoxifen: role of drug interaction with alpha 1 acid glycoprotein
50. CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma
51. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes
52. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells
53. Activation of MDR-1 (P-glycoprotein) gene expression in human cells by protein kinase C agonists
54. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs
55. Amiodarone-induced enhancement of doxorubicin and 4′-deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo
56. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug resistant human cells
57. BIBW 22, a dipyridamole analogue, acts as a bifunctional modulator on tumor cells by influencing both P-glycoprotein and nucleoside transport
58. Function and regulation of the human multidrug resistance gene
59. An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene
60. Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cells
61. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
62. Cyclosporin A binding to calmodulin: a possible site of action on T lymphocytes
63. Multidrug resistance activity in human lymphocytes
64. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites
65. Increased vinblastine binding to membrane vesicles from multidrug-resistant KB cells
66. Certain calcium channel blockers bind specifically to multidrug resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein
67. Receptor adaptations to centrally acting drugs
68. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma; detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy
69. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation
70. Attempted suicide with verapamil
71. Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance
72. Structural requirements of simple organic cations for recognition by multidrug-resistant cells
73. In vitro model for intrinsic drug resistance: effects of protein kinase C activators on the chemosensitivity of cultured human colon cancer cells
74. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype
75. The immunosuppressive macrolides FK506 and rapamycin act as reciprocal antagonists in murine T cells
76. Inhibition of the multidrug transporter, P-glycoprotein, by the cyclosporin analogue PSC 833, cyclosporine and verapamil
77. Tumor resistance to chemotherapy associated with expression of the multidrug resistance phenotype
78. P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD
79. Isolation of amplified and overexpressed DNA sequences from Adriamycin-resistant human breast cancer cells
80. Multidrug resistance and mutagenesis
81. Transient protection of cultured human cells against antitumor agents by l Z-O-tetradecanoylphorbol-13-acetate
82. Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer
83. Phorbol esters induce multidrug resistance in human breast cancer cells
84. Dipyridamole
85. Vergleichende untersuchungen uber die Ca++-antagonistischen grundwirkungen von niludipin (Bay a 7168) und nifedipin (Bay a 1040) auf myokard, myomertrium und glatte gefassmuskulatur
86. Megestrol acetate reverses multidrug resistance and interacts with P-glycoprotein
87. Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines
88. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines
89. Pharmacology of drugs that alter multidrug resistance in cancer
90. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance
91. Effect of buthionine sulfoximine on toxicity of verapamil and doxorubicin to multidrug resistant cells and to mice
92. Modulation of induced resistance to Adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate
93. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporin binding protein
94. The pharmacology and clinical uses of tamoxifen
95. Enhancement of sensitivity to Adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine
96. Differential effect of the calmodulin inhibitor trifluoperazine in modulating cellular accumulation, retention and cytotoxicity of doxorubicin in progressively doxorubicin-resistant L1210 mouse leukemia cells
97. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage
98. Modulation of doxorubicin-incuced chromosomal damage by calmodulin inhibitors and its relationship to cytotoxicity in progressively doxorubicin-resistant tumor cells
99. Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (Adriamycin)-resistant P388 mouse leukemia cells
100. Factors governing the modulation of vinca-alkaloid resistance in doxorubicin-resistant cells by the calmodulin inhibitor trifluoperazine
101. Effect of the calmodulin inhibitor trifluoperazine on phosphorylation of P-glycoprotein and topoisomerase II: relationship to modulation of subcellular distribution, DNA damage and cytotoxicity of doxorubicin in multidrug resistant L1210 mouse leukemia cells
102. Relationship between expression of P-glycoprotein and efficacy of trifluoperazine in multidrug-resistant cells
103. Role of the calmodulin inhibitor trifluoperazine on the induction and expression of cell cycle traverse perturbations and cytotoxicity of daunorubicin and doxorubicin (Adriamycin) in doxorubicin-resistant P388 mouse leukemia cells
104. Overcoming multidrug resistance in Chinese hamster ovary cells in vitro by cyclosporin A (Sandimmune) and non-immunosuppressive derivatives
105. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications
106. Reduced cyclosporin accumulation in multidrug-resistant cells
107. A Y-box consensus sequence is required for basal expression of the human multidrug resistance (mdr1) gene
108. Expression of a multidrug resistance gene in human cancers
109. Multidrug resistance in human cancer
110. Protein kinase C isoforms in multidrug resistant P388/ADR cells: a possible role in daunorubicin transport
111. Bilirubin: a physiological substrate for the multidrug transporter
112. Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells
113. Estradiol-17β-(β-D-glucuronide): a cholestatic organic anion and substrate for the multidrug resistance transporter
114. Augmentation of 5-flourouracil cytotoxicity in human colon cancer cells by dipyridamole
115. Mammalian multi-drug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins
116. Isolation and expression of a complementary DNA that confers multidrug resistance
117. D-verapamil and L-verapamil are equally effective in increasing vincristine accumulation in leukemic cells in vitro
118. Rational design and preclinical pharmacology of drugs for reversing multidrug resistance
119. Sensitivity of K562 human chronic myelogenous leukemia blast cells transfected with a human multidrug resistance cDNA to cytotoxic drugs and differentiating agents
120. The role of the phorbol ester receptor/protein kinase C in the sensitivity of leukemic cells to Anthracyclines
121. Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells
122. Calmodulin, cyclophilin and cyclosporin A
123. Calmodulin: a potential target for cancer chemotherapeutic agents
124. Phase I trial of combined therapy with bleomycin and the calmodulin antagonist, trifluoperazine
125. Comparison of the efficacy of a phenothiazine and bisquinaldinium calmodulin antagonist against multidrug resistant cell lines
126. Activity of cyclosporin A and a non-immunosuppressive cyclosporin on multidrug resistant leukemic cell lines
127. Modulation of doxorubicin (DOX) resistance by cyclosporin A (CsA) and a nonimmunosuppresive homolog
128. Effect of activation of protein kinase C on Vinca alkaloid transport in multidrug resistant cells
129. Phosphorylation of the Mr 170,000 to 180,000 glycoprotein specific to multidrug-resistant tumor cells: effects of verapamil, trifluoperazine, and phorbol esters
130. Functional role for the 170- to 180-kDa glycoprotein specific to drug-resitant tumor cells as revealed by monoclonal antibodies
131. Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells
132. Purification of the 170- to 180-kilodalton membrane glycoprotein associated with multidrug resistance: 170- to 180-kilodalton membrane glycoprotein is an ATPase
133. Cyclophilin: a specific cytosolic binding protein for cyclosporin A
134. Verapamil-mediated sensitization of doxorubicin-selected pleiotropic resistance in human sarcoma cells: selectivity for drugs which produce DNA scission
135. Expression and functional activity of P-glycoprotein in cultured cerebral capillary endothelial cells
136. Calcium channel blocker enhancement of anticancer drug cytotoxicity — a review
137. Complete nucleotide sequence and identification of membrane components of the histidine transport operon of S. typhimurium
138. A family of related ATP-binding subunits coupled to many distinct biological processes in bacteria
139. Overexpression of P-glycoprotein in mammalian tumor cell lines after fractionated X-irradiation in vitro
140. Effect of erythromycin and tumour necrosis factor on the drug resistance of multidrug-resistant cells: reversal of drug resistance by erythromycin
141. Reversal of drug resistance by erythromycin: erythromycin increases the accumulation of actinomycin D and doxorubicin in multidrug-resistant cells
142. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein
143. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas
144. Comparison of the synergistic potentiation of etoposide, doxorubicin and vinblastine cytotoxicity by dipyridamole
145. Dipyridamole enhancement of etoposide sensitivity
146. Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines
147. Assay of dopamine receptors with [α-3H] flupenthixol
148. Antipsychotic drugs: configurational stereoisomers
149. An inhibitor of protein kinase C, 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine (H-7) inhibits TPA-induced reduction of vincristine uptake from P388 murine leukemic cell
150. Reversal of resistance to vincristine in P388 leukemia by various polycyclic clinical drugs, with a special emphasis on quinacrine
151. Non-antitumor vinca alkaloids reverse multidrug in P388 leukemia cells in vitro
152. Reversal of multidrug resistance by non-antitumor anthracycline analogs
153. Increased P-glycoprotein expression and multidrug-resistant gene (mdr1) amplification are infrequently found in fresh acute leukemia cells
154. Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446
155. Estradiol induction of rhodamine 123 efflux and the multidrug resistance pump in rat pituitary tumor cells
156. Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro
157. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia
158. Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer
159. Serum concentrations of cis(Z)-flupenthixol and prolactin in chronic schizophrenic patients treated with flupenthixol and cis(Z)-flupenthixol decanoate
160. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
161. Quantitation of tumor cell expression of the P-glycoprotein (mdr1) gene in human breast carcinoma clinical specimens
162. Human breast carcinoma cell levels of MDR-1 (P-glycoprotein) correlate in vivo inversely and reciprocally with tumor progesterone receptor content
163. Reversal of multidrug resistance by two novel indole derivatives
164. Resistance to tetracycline, a hydrophilic antibiotic, is mediated by P-glycoprotein in human multidrug-resistant cells
165. Circumvention of multidrug resistance in human carcinoma KB cells by polyether antibiotics
166. Protein kinase recognition sequence motifs
167. Consensus sequences as substrate specificity determinants for protein kinases and protein phosphatases
168. Anthracycline resistance in P388 murine leukemia and its circumvention by calcium antagonists
169. Promotion of daunorubicin uptake and toxicity by the calcium antagonist tiapamil and its analogs
170. Interaction of cyclosporin A with antineoplastic agents
171. Role of the glutathione redox cycle in acquired and de novo multidrug resistance
172. Potentiation of Adriamycin cytotoxicity by dipyridamole against HeLa cells in vitro
173. Multiple resistance mechanisms in Chinese hamster cells resistant to 9-hydroxy-ellipticine
174. Combination of cyclosporin A and buthionine sulfoximine as a pharmacological strategy for circumvention of multidrug resistance in small cell lung cancer cell lines selected for resistance to doxorubicin
175. Enhanced bleomycin-induced DNA damage and cytotoxicity with calmodulin antagonists
176. Does the binding of cyclosporine to calmodulin result in immunosuppression?
177. Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model
178. Effects of a new triazinoaminopiperidine derivative on Adriamycin accumulation and retention in cells displaying P-glycoprotein-mediated multidrug resistance
179. Identification of P-glycoprotein in renal brush border membranes
180. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance
181. Analysis of P-glycoprotein phosphorylation in HL-60 cells isolated for resistance to vincristine
182. Identification of 5′ and 3′ sequences involved in the regulation of transcription of the human mdr1 gene in vivo
183. A newly synthesized bifunctional inhibitor, W-77, enhances Adriamycin activity against human ovarian carcinoma cells
184. Multidrug resistance (mdr1) gene expression on adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity
185. The yeast STE6 gene encodes a homologue of the mammalian multidrug resistance P-glycoprotein
186. Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody
187. Phosphorylation of the multidrug resistance associated glycoprotein
188. Protein phosphorylation in mulstidrug resistant Chinese hamster cells
189. Monoclonal antibody MRK16 reverses the multidrug reistance of multidrug-resistant transgenic mice
190. Modulation of the expression of a multidrug resistance gene by differentiating agents
191. Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial
192. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil
193. Intermitent high-dose tamoxifen as a potential modifier of multidrug resistance
194. Inhibitory action of chlorpromazine, dibucaine, and other phospholipid-interacting drugs on calcium-activated, phospholipid-dependent protein kinase
195. ATP/Mg2+-dependent binding of vincristine to the plasma membrane of multidrug-resistant K562 cells
196. Reversal of multidrug resistance by an immunosuppressive agent FK-506
197. Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance
198. Competitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug-resistant K562 cells without calcium ion involvement
199. Steroid hormones inhibit binding of Vinca alkaloid to multidrug reistance related P-glycoprotein
200. Reversal of multidrug resistance by synthetic isoprenoids in the KB human cancer cell line
201. Potentiation of methotrexate toxicity by dipyridamole
202. Comparative pharmacology of flupenthixol and some reference neuroleptics
203. Central depressant activity of some thiaxanthene derivatives
204. The molecular heterogeneity of protein kinase C and its implications for cellular regulation
205. Effect of a dihydropyridine analogue, 2-[benzyl(phenyl)amino]ethyl-1,4-dihydro-2,6-dimethyl-5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1-(2-morpholino-ethyl)-4-(3-nitrophenyl)-3-pyridinecarboxylate on reversing in vivo resistance of tumor cells to adriamycin
206. Analysis of structural features of dihydropyridine analogs needed to reverse multidrug resistance and to inhibit photoaffinity labeling of P-glycoprotein
207. Effect of cyclosporin A on daunorubicin accumulation in multidrug-resistant P388 leukemia cells measured by real-time flow cytometry
208. Transient enhancement of multidrug resistance by the bile acid deoxycholate in murine fibrosarcoma cells in vitro
209. Level of protein kinase C activity correlates directly with resistance to Adriamycin in murine fibrosarcoma cells
210. Inhibition of protein kinase C by tamoxifen
211. A novel N-myristylated synthetic octapeptide inhibits protein kinase C activity and partially reverses murine fibrosarcoma cell resistance to Adriamycin
212. Purification and characterization of NF-R1 that regulates the expression of the human multidrug resistance (MDR1) gene
213. The stucture, expression, and properties of additional members of the protein kinase C family
214. Protein kinase C ζ subspecies from rat brain: its structure, expression and properties
215. A phorbol ester receptor/protein kinase, nPKCη, a new member of the protein kinase C family predominantly expressed in lung and skin
216. Synergistic interaction of cyclosporin A and verapamil on vincristine and daunorubicin resistance in multidrug-resistant human leukemia cells in vitro
217. Enhancement of etoposide-induced cytotoxicity by cyclosporin A
218. Inhibition of tubulin-microtubule polymerization by drugs of the Vinca alkaloid class
219. Verapamil and Adriamycin in the treatment of drug-resistant ovarian cancer patients
220. Inhibition of protein kinase C by antineoplastic agents: implications for drug resistance
221. Mechanism of quinidine and chlorpromazine inhibition of sarcotubular ATPase activity
222. Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance
223. Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody
224. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration
225. Up regulation of the phorbol ester receptor-protein kinase C in HL-60 variant cells
226. Progesterone regulates the murine multidrug resistance mdr1b gene
227. In vitro and in vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative
228. Reversal of multidrug resistance in human KB cell lines by structural analogs of verapamil
229. MDR1 gene expression and treatment outcome in acute myeloid leukemia
230. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex
231. The activity of verapamil as a resistance modifier in vitro in drug resistant human tumor cell lines is not stereospecific
232. Protein kinase C in Adriamycin action and resistance in mouse sarcoma 180 cells
233. Human multidrug resistant KB cells overexpress protein kinase C: involvement in drug resistance
234. Stereoselective blockade of the dopamine receptor and the X-ray structures of alpha and beta-flupenthixol
235. Verapamil reversal of clinical doxorubicin resistance in human cancer
236. Inhibition of calmodulin by phenothiazines and related drugs: structure-activity relationships
237. Binding of an optically pure photoaffinity analogue of verapamil, LU-49888, to P-glycoprotein from multidrug-resistant human leukemic cell lines
238. Calmodulin activation of red blood cell (Ca2++Mg2+)-ATPase and its antagonism by phenothiazines
239. Structure-activity relationship of compounds that restore sensitivity to doxorubicin in drug-resistant P388 cells
240. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by perhexiline maleate
241. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues
242. Reversal of multidrug resistance by phenothiazines and structurally related compounds
243. Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells
244. Circumvention of Adriamycin resistance by dipyridamole analogues: a structure-activity relationship study
245. Drug interactions with calmodulin: the binding site
246. Genetic and biochemical characterization of multidrug resistance
247. Multidrug resistance in leukemia
248. Reversal of Vinca alkaloid resistance by anti-P-glycoprotein monoclonal antibody HYB-241 in a human tumor xenograft
249. 8-Cl-cAMP induces truncation and down-regulation of the RI-alpha subunit and up-regulation of the RII-beta subunit of cAMP-dependent protein kinase leading to type II holoenzyme-dependent growth inhibition and differentiation of HL-60 leukemia cells
250. Reversal of resistance to Adriamycin by 8-chloro-cyclic AMP in Adriamycin-resistant HL-60 leukemia cells in associated with reduction of type I cyclic AMP-dependent protein kinase and cyclic AMP response element-binding protein DNA-binding activities
251. The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo
252. Expression of the mdr-1/P-170 gene in patients with acute lymphoblastic leukemia
253. Phenothiazines and related compounds disrupt mitochondrial energy production by a calmodulin-independent reaction
254. Human P-glycoprotein transports cyclosporin A and FK506
255. Inhibition of azidopine binding to the multidrug resistance related gp 150–180 (P-glycoprotein) by modulators of multidrug resistance
256. Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil
257. Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers
258. Photoaffinity labeling of P-glycoprotein in multidrug resistant cells with photoactive analogs of colchicine
259. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer
260. Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining
261. Letter to the editor
262. Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073
263. Phospholipid-sensitive calcium-dependent protein kinase: inhibition by antipsychotic drugs
264. Overexpression of a Mr 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance
265. Chemistry and biology of the immunophilins and their immunosuppressive ligands
266. The mechanism of action of cyclosporin and FK506
267. Daunorubicin and vincristine vinding to plasma membrane vesicles from daunorubicin-resistant and wild type Ehrlich ascites tumor cells
268. Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cells
269. Modulation of drug sensitivity by dipyridamole in multidrug resistant tumor cells in vitro
270. Modulation of vinblastine sensitivity by dipyridamole in multidrug resistant fibrosarcoma cells lacking mdr1 expression
271. Effect of bisbenzylisoquinoline (biscoclaurine) alkaloids on multidrug resistance in KB human cancer cells
272. Multidrug (pleiotropic) resistance in the human sarcoma cell line MES-SA
273. Effects of cyclosporin A and verapamil on the intracellular daunorubicin accumulation in Chinese hamster ovary cells with increasing levels of drug-resistance
274. Mechanisms of resistance to daunorubicin in Ehrlich ascites tumour cells
275. Circumvention of resistance to daunorubicin by N-acetyldaunorubicin in Ehrlich ascites tumor
276. Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma
277. Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM
278. Modulation of multidrug-resistant multiple myeloma by cyclosporin
279. Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed or resistant non-Hodgkin's lymphoma: evidence for a schedule-dependent effect favoring infusional administration of chemotherapy
280. A gene in the human major histocompatibility complex class II regions controlling the class I antigen presentation pathway
281. Prochloroperazine as a doxorubicin-efflux blocker; phase I clinical and pharmacokinetic studies
282. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16
283. Apparent stronger expression in the human adrenal cortex than in the human adrenal medulla of Mr 170,000–180,000 P-glycoprotein
284. Azidopine noncompetively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells
285. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crosseactivity of one antibody with a muscle protein
286. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
287. Sequences encoded in the class II region of the MHC related to the “ABC” superfamily of transporters
288. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine
289. Circumvention of drug resistance with calcium channel blockers and monoclonal antibodies
290. Inhibition of multidrug-resistant human tumor growth in athymic mice by anti-P-glycoprotein monoclonal antibodies
291. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and Adriamycin in drug-resistant tumor cells
292. Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers
293. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil
294. Increased accumulation of vincristine and Adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors
295. Potentiation of vincristine and Adriamycin in human hematopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors
296. Potentiation of antitumor agents by calcium channel blockers with special reference to cross-resistance patterns
297. Modification of cytotoxic drug resistance by non-immuno-suppressive cyclosporins
298. A possible role for cyclosporins in cancer chemotherapy
299. Cyclosporin A and its analogues as modifiers of Adriamycin and vincristine resistance in a multidrug resistant human lung cancer cell line
300. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone
301. Volume-regulated chloride channels associated with the human multidrug resistance P-glycoprotein
302. In vitro and in vivo modulation of multidrug resistance with amiodarone
303. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)
304. Cyclosporin A inhibits protein kinase C activity: a contributing mechanism in the development of nephrotoxicity?
305. Evidence that the antiproliferative effect of verapamil on afferent and efferent immune responses is independent of calcium channel inhibition
306. Toremifene and its metabolites enhance doxorubicin accumulation in estrogen receptor negative multidrug resistant human breast cancer cells
307. Reversal of multidrug resistance with R-verapamil and analysis of mdr-1 expression in patients with lymphoma refractory to EPOCH chemotherapy
308. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma
309. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance
310. Overcoming drug resistance in cancer cells with synthetic isoprenoids
311. Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus
312. Azidopine photoaffinity labeling of multidrug resistance-associated glycoproteins
313. Differential transport properties of two mdr gene products are distinguished by progesterone
314. Reversal of multidrug resistance by new dihydropyridines with lower calcium antagonistic activity
315. Transfection with protein kinase C α confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein
316. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells
317. Chloroquine enhancement of anticancer drug cytotoxicity in multiple drug resistant human leukemic cells
318. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells
319. Interaction of daunomycin and its derivatives with DNA